Drugs / Ad5-yCD/mutTKSR39rep-hIL12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03281382 | Jul 2017 → May 2019 | malignant pancreatic neoplasm | Henry Ford Health System | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5-yCD/mutTKSR39rep-hIL12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03281382 ↗ |
| Route | Other | “single intratumoral injection” NCT03281382 ↗ |